Rocket Pharmaceuticals: enters loan agreement for up to $150,000,000

What happened

• The filing says Rocket Pharmaceuticals entered into a Loan and Security Agreement with Hercules Capital, Inc. as administrative agent and a group of lenders providing for up to $150,000,000 of senior secured term loans. A Tranche 1-A advance of $35,000,000 was funded on Sep 30, 2026.
• The filing says the company issued warrants to the lenders to purchase up to an aggregate of 1,755,853 shares of common stock at an exercise price of $2.99 per share; warrants to purchase an aggregate of 409,699 shares became exercisable following the Tranche 1-A closing.
• The filing says the company furnished a press release and an investor presentation on Oct 6, 2026.

Key details

• Term loan tranches available: Tranche 1-A $35,000,000 (funded Sep 30, 2026), Tranche 1-B $20,000,000 (available at borrower option through Jun 30, 2027), Tranche 1-C $15,000,000 (available through Sep 30, 2027), Tranche 2 $30,000,000 (available after achieving the Tranche 2 Milestone through Dec 15, 2028 or 60 days after milestone), Tranche 3 up to $50,000,000 (subject to lenders’ investment committee approval).
• Interest rate equals the greater of prime rate and 6.75% plus 2.40%; interest-only payments through Apr 1, 2029 (subject to extensions tied to milestones); maturity Oct 1, 2030 (extendable to Oct 1, 2031 upon Tranche 2 Milestone).
• Borrower obligations are secured by a first-priority security interest in substantially all assets, including intellectual property; the loan includes a minimum cash covenant requiring qualified cash equal to a percentage of outstanding term loans (ranging from 35% to 75% depending on milestone achievement), not tested if market capitalization exceeds $600,000,000.
• Prepayment fees apply (3.00% if prepaid before the first anniversary, 2.00% between first and second anniversary, 1.00% thereafter until maturity); end-of-term charges and customary fees also apply.

Why it may matter

• The filing reports Item 1.01 (entry into a material definitive agreement — the Loan and Security Agreement), Item 2.03 (creation of a direct financial obligation — the Term Loans), Item 3.02 (unregistered sales of equity securities — issuance of warrants to lenders), and Item 7.01 (regulation FD disclosure — press release and investor presentation).
• A filing does not show why the insider traded or why the company acted.